Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

被引：0
|
作者：
Fizazi, K. [1 ]
Luz, M. [2 ]
Ulys, A. [3 ]
Ortiz, J. [4 ]
Srinivasan, S. [5 ]
Kurland, E. [6 ]
Shore, N. D. [7 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France
[2] Hosp Erasto Gaertner, Dept Urol, Curitiba, Parana, Brazil
[3] Vilnius Univ, Inst Oncol, Vilnius, Lithuania
[4] Bayer HealthCare, Dept Med Affairs, Whippany, NJ USA
[5] Bayer HealthCare, Dept Stat, Whippany, NJ USA
[6] Bayer HealthCare, Clin Dev, Whippany, NJ USA
[7] Carolina Urol Res Ctr & Genesis Care, Dept Urol, Atlant Urol, Myrtle Beach, SC USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1193
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study
    Fizazi, K.
    Shore, N.
    Smith, M.
    Carles, J.
    Lebret, T.
    Lietuvietis, V.
    Mahammedi, H.
    Rannikko, A.
    Vjaters, E.
    Werbrouck, P.
    Miskic, M.
    Kuss, I.
    Le Berre, M.
    Borghesi, G.
    Sarapohja, T.
    Fayerabend, S.
    EUROPEAN UROLOGY, 2021, 79 : S1740 - S1741
  • [22] Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study
    Krabbe, L. -M
    Fizazi, K.
    Shore, N.
    Smith, M.
    Carles, J.
    Lebret, T.
    Lietuvietis, V
    Mahammedi, H.
    Rannikko, A.
    Vjaters, E.
    Werbrouck, P.
    Miskic, M.
    Kuss, I
    Le Berre, M. A.
    Borghesi, G.
    Sarapohja, T.
    Feyerabend, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 265 - 265
  • [23] The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
    Tripathy, Sambit
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 293 - 294
  • [24] Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
    Vjaters, E.
    Fizazi, K.
    James, N. D.
    Tammela, T. L.
    Matsubara, N.
    Priou, F.
    Beuzeboc, P.
    Lesimple, T.
    Bono, P.
    Kataja, V
    Garcia, J. A.
    Protheroe, A.
    Aspegren, J.
    Joensuu, H.
    Kuss, I
    Thiele, S.
    Fiala-Buskies, S.
    Jones, R. H.
    EUROPEAN UROLOGY, 2022, 81 : S786 - S787
  • [25] Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
    Appukkuttan, Sreevalsa
    Farej, Ryan
    Miles, LaStella
    Purser, Molly
    Wen, Lonnie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (02): : 166 - 174
  • [26] Re: Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 205 (04): : 1226 - 1227
  • [27] Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
    Jones, Robert Hugh
    Fizazi, Karim
    James, Nicholas D.
    Tammela, Teuvo L.
    Matsubara, Nobuaki
    Priou, Frank
    Beuzeboc, Philippe
    Lesimple, Thierry
    Bono, Petri
    Kataja, Vesa
    Garcia, Jorge A.
    Protheroe, Andrew
    Shore, Neal
    Aspegren, John
    Joensuu, Heikki
    Kuss, Iris
    Fiala-Buskies, Sabine
    Vjaters, Egils
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (04) : 786 - 789
  • [28] FDA Approves Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 498 - 498
  • [29] Prespecified interim analysis of the DARolutamide ObservationaL (DAROL) study in Black/African American patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Yu, Evan Y.
    Pieczonka, Christopher
    Suzuki, Hiroyoshi
    Briganti, Alberto
    Luz, Murilo
    Murphy, Declan
    Adorjan, Patrick
    Ghadessi, Mercedeh
    Verholen, Frank
    Armstrong, Andrew J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [30] THIRD INTERIM ANALYSIS (IA3) OF THE DAROLUTAMIDE OBSERVATIONAL (DAROL) STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
    Gotto, Geoffrey
    Suzuki, Hiroyoshi
    Luz, Murilo
    Briganti, Alberto
    Yu, Evan Y.
    Pieczonka, Christopher
    Murphy, Declan
    Malone, Ryan
    Hamilton, Joelle
    Chan, Jonathan E.
    Sieber, Paul
    Given, Robert W.
    Adorjan, Patrick
    Ghadessi, Mercedeh
    Verholen, Frank
    Armstrong, Andrew J.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E63 - E63
12345